Table 2.
Studies Characterizing the Prevalence and Associated Mortality Rates of Bloodstream Infections (BSIs) due to Extended-Spectrum β-lactamase-producing Enterobacteriaceae (ESBL-E) in Patients with Hematologic Malignancies.
| Reference | Country | Years | Organism(s) | % of Isolates that were ESBL-E | Mortality after ESBL-E BSI vs. non-ESBL-E BSI | Mortality Type |
|---|---|---|---|---|---|---|
| [Guidol 2010] | Spain | 2006-2009 | Escherichia coli | 17% (13/76) | 38% vs. 7%1 | 30-day |
| [Cornejo-Jaurez 2012] | Mexico | 2004-2009 | Escherichia coli | 31% (205/760)2 | 34% vs. 19%1 | Overall |
| [Kang 2012] | Korea | 2008-2009 |
Escherichia. coli Klebisella pneumoniae |
24% (37/156) | 45% vs. 14%1 | 30-day |
| Metan [2013] | Turkey | 2006-2011 | Enterobacteriaceae | 33% (40/120) | 13% vs. 16% | 7-day |
| Ha [2013] | Korea | 2010-2012 | Escherichia coli | 32% (42/130) | 14% vs. 10% | 30-day |
| Kim [2013] | Korea | 2007-2008 |
Escherichia coli Klebisella pneumoniae |
26% (26/101) | 15% vs. 5% | 30-day |
| Trecarichi [2015] | Italy | 2009-2012 | Enterobacteriaceae | 37% (98/265)3 | 26% vs. 5%1 | 21-day |
1
P value < 0.05 for the comparison.
2
The proportion of E. coli that were ESBL-producing increased from 15% in 2004 to 65% in 2009.
3
This study did not assess isolates for ESBL production. 3rd-generation cephalosporin resistance was used as a surrogate for ESBL production in this analysis.